Cell­tri­on teams up with an­oth­er Ko­re­an bio­phar­ma in an­ti­body dis­cov­ery deal

Two Ko­re­an com­pa­nies have signed a joint R&D dis­cov­ery agree­ment, with the po­ten­tial to earn in the nine-fig­ures.

Clin­i­cal-stage bio­phar­ma Genuv has part­nered up with Cell­tri­on to dis­cov­er an­ti­bod­ies us­ing the for­mer’s Shine Mouse plat­form, which they hope could po­ten­tial­ly open up more R&D projects to­geth­er in the fu­ture. There’s no up­front cash, but Genuv will re­ceive mile­stone pay­ments of up to $25 mil­lion if Cell­tri­on de­cides to op­tion a pro­gram in­to the clin­ic, and up to $680 mil­lion in mile­stones per pro­gram if its sales sur­pass $7.5 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA